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To select maximally-efficacious, minimally-toxic regimens
of combination tumor- and immune-targeted therapy, pre-
clinical testing in immune-competent models is required.
We previously demonstrated 4-1bb(CD137) stimulation
augmented the innate immune response mediated by
CD137+activated natural killers (NK) cells and the subse-
quent CD8+ T cell adaptive immune response when admi-
nistered after tumor-targeting, ADCC-competent, mAbs
targeting CD20, HER2, and EGFR. As four ongoing clini-
cal trials (NCT01471210, NCT01775631, NCT02110082,
NCT01307267) investigate this strategy, the CD8+ T cell
response stimulated by 4-1bb was determined pre-clini-
cally to be further augmented by PD-1/PD-L1 blockade,
and a clinical trial is planned (NCT02179918). Taken
together, we hypothesized, sequential tumor-targeting
with anti-CD20 mAb, Rituximab, followed by dual
immune-targeting with anti-CD137 agonism and PD-1/
PD-L1 blockade would be efficacious and tolerable due to
non-overlapping immune mechanisms and toxicity
profiles.
Preclinical modeling was performed in a therapeutic,
syngenic, A20 lymphoma BALB/c model combining anti-
CD20 mAb (IgG2a-18B12, delivered intraperitoneally, i.p.
on d5) with agonistic anti-CD137 mAb (IgG2a-2A, i.p. d6)
and anti-PD-1 mAb (IgG2a-RMPI-14, i.p. d6) with intratu-
moral (i.t.) and circulating (c.) immune responses pheno-
typed by flow cytometry and time of flight mass cytometry
(CyTOF). Combination immunotherapy with anti-CD137
and anti-PD1 was superior to either monotherapy without
anti-CD20 treatment in a dose-dependent manner (p<.001
tumor-growth, p < .001 survival), though no mice were
cured long-term. When administered following anti-CD20
treatment, combination immunotherapy with anti-CD137
and anti-PD1 was superior to either monotherapy in a
sequence-dependent manner (p<.001 tumor-growth, and
p < .001 survival) with all mice cured long-term and pro-
tected from re-challenge when anti-CD20 preceded com-
bination immunotherapy. Target expression was dynamic,
as exemplified by highest CD137 expression on i.t.Tregs,
followed by i.t.CD8+ T cells. Following anti-CD20 mAb
treatment, 1) CD137 expression increased 5-10x on i.t.
NKs and 2-6x increase on c.NKs; 2) PD-L1 expression
increased on A20 tumor and i.t.CD8+ T cells, and mini-
mally on i.t.NKs; and 3) PD-1 expression increased on i.t.
Tregs, i.t.CD8+ T cells, and i.t.NKs. Treatment with anti-
CD137 agonist and PD-1 blockade 1) increased the ratio
of i.t.NKs/Tregs and c.CD8+ T cells/Tregs, and 2)
increased i.t. and c.CD8+ T cell tumor-specific IFN-g
secretion and i.t. and c.NK cell degranulation. Laboratory
and necropsy studies identified B cell lymphopenia and
mild transaminitis which was notably marked with combi-
nation immunotherapy.
We conclude that sequential tumor-targeting followed
by dual immune-targeting is highly-efficacious with pre-
dictable toxicity and should be considered for clinical
translation to augment three therapies with only mar-
ginal activity as monotherapy in advanced, relapsed/
refractory lymphoma.2Stanford University, Stanford, CA, USA
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